Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

149.02 -0.36 (-0.24%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 524,903
Open 148.67
Bid (Size) 147.00 (6)
Ask (Size) 150.00 (3)
Prev. Close 149.38
Today's Range 147.07 - 149.41
52wk Range 145.07 - 268.30
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Large-Cap Stocks In Trouble - Saturday, Dec. 21
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Topics Stocks / Equities
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga

Performance

YTD
-44.34%
-44.34%
1 Month
-6.11%
-6.11%
3 Month
-23.23%
-23.23%
6 Month
-33.23%
-33.23%
1 Year
-42.84%
-42.84%

More News

Read More
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory?
Via Benzinga
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Via Benzinga
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Assessing Biogen: Insights From 19 Financial Analysts
Via Benzinga
Peeling Back The Layers: Exploring Biogen Through Analyst Insights
Via Benzinga
Evaluating Biogen: Insights From 17 Financial Analysts
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
Via The Motley Fool
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Via Benzinga
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
From Biogen Inc.
Via GlobeNewswire
Biogen Analysts Slash Their Forecasts After Q3 Results
Via Benzinga
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
Via Investor's Business Daily
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Via Benzinga
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
From Biogen Inc.
Via GlobeNewswire
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Biogen (BIIB) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
Via Benzinga
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.